Abstract
SOMATOSTATIN has been reported to diminish basal insulin levels1 and to inhibit insulin secretion stimulated by glucose,2 arginine,3 glucagon,4 and tolbutamide4 in normal man. These effects of somatostatin administration have not been associated with serious untoward effects. Therefore, it has been suggested5 that somatostatin might be efficacious in suppressing autonomous hypersecretion of insulin by pancreatic islet-cell adenomas or carcinomas. In the following case, somatostatin was indeed found to be effective in suppressing insulin hypersecretion in a woman with metastatic pancreatic islet-cell carcinoma. Somatostatin also reduced elevated serum gastrin levels. Case Report A 54-year-old woman was admitted to the University of . . .
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
